立体定向体部放疗单独或联合免疫治疗肾癌的系统综述
结果显示,在局限期高危或无法手术患者中,SABR是(部分)肾切除术的有效替代,耐受性好且局部控制极佳;寡转移期SABR可延迟系统治疗;转移期SABR联合免疫治疗的多项早期试验显示前景,尤其多病灶(优先全部病灶)SABR联合免疫治疗最具潜力,但需未来大型随机试验验证。
要点
- 局限期高危或无法手术的RCC患者,SABR是(部分)肾切除术的有效替代,耐受性好且局部控制极佳。
- 寡转移期两项2期试验显示SABR替代系统治疗可行,多数患者1年时无需系统治疗。
- 转移期SABR联合免疫治疗的多项早期试验显示前景,多病灶SABR联合免疫治疗最具潜力。
核心结论
- SABR是局限期RCC无法行(部分)肾切除术时的有效替代治疗。
- 转移期SABR单独或联合免疫治疗的早期试验结果鼓励未来开展大型随机试验。
研究设计与样本
- 系统综述,按照PRISMA声明于2025年1月在PubMed和Cochrane数据库检索。
主要发现
- 局限期:15项前瞻性研究证明SABR是高危或医学无法手术患者(部分)肾切除术的有价值替代,耐受性好且局部控制极佳。
- 寡转移期:两项2期试验研究SABR替代系统治疗,结果鼓舞,多数患者1年时无需系统治疗。
- 转移期:多项1期和2期试验研究SABR联合免疫治疗,最有前景的选择似乎是对多个(优先全部)病灶行SABR。
- 非转移患者中尚无SABR联合免疫治疗的前瞻性研究报道。
临床怎么用
- 局限期RCC患者若无法行(部分)肾切除术,可考虑SABR作为替代治疗。
- 寡转移期RCC患者可考虑SABR替代系统治疗以延迟系统治疗启动。
- 转移期RCC患者参与SABR联合免疫治疗的临床试验时,多病灶(优先全部病灶)SABR联合免疫治疗是颇具吸引力的策略。
- 减瘤性SABR和寡进展病灶SABR联合免疫治疗是未来有吸引力的策略。
局限性
- 转移期SABR联合免疫治疗证据来自早期(1期和2期)试验,需未来大型随机试验验证。
- 非转移患者中缺乏SABR联合免疫治疗的前瞻性研究数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Despite its radioresistant reputation, renal cell carcinoma (RCC) is sensitive to high dose per fraction stereotactic ablative body radiotherapy (SABR). As SABR also triggers immunomodulatory effects, a combination of SABR and immunotherapy for RCC might improve patient outcomes. The current systematic review will discuss all prospective studies on SABR alone or combined with immunotherapy. METHODS: A systematic review was conducted in January 2025 according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses statement on the PubMed and Cochrane databases. Thirty-eight studies were included in this review. KEY FINDINGS AND LIMITATIONS: In the primary setting, 15 prospective studies have proved SABR to be a valuable alternative for (partial) nephrectomy for high-risk or medically inoperable patients, with good tolerability and excellent local control. No prospective studies have reported on SABR combined with immunotherapy in nonmetastatic patients. In the oligometastatic setting, two phase 2 trials have investigated SABR in lieu of systemic treatment. This showed encouraging results, with the majority of patients being free from systemic therapy at 1 yr. SABR combined with immunotherapy in the metastatic setting has been investigated in multiple phase 1 and 2 trials, where the most promising option seems to be SABR to multiple-preferentially all-lesions. Cytoreductive SABR and SABR to oligoprogressive lesions combined with immunotherapy are attractive future strategies. CONCLUSIONS AND CLINICAL IMPLICATIONS: SABR is a valid alternative in localised RCC when (partial) nephrectomy is not an option. In the metastatic setting, several early-phase trials have investigated SABR alone and in combination with immunotherapy, warranting future large, randomised trials.
引用
- Sundahl N, Albiges L, Choueiri TK, et al. Stereotactic Body Radiation Therapy Alone or in Combination with Immunotherapy in Kidney Cancer: A Systematic Review. Eur Urol. 2025. PMID: 40221282. doi:10.1016/j.eururo.2025.03.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。